摘要
目的:观察赫赛汀联合NP(长春瑞滨+顺铂)方案治疗蒽环类耐药晚期乳腺癌患者的临床疗效和毒副反应。方法:32例蒽环类耐药的晚期乳腺癌患者采用赫赛汀首次剂量为8mg/kg,随后减量至6mg/kg,化疗前1天使用。长春瑞滨25mg/m2静脉滴注,第1,8天使用。顺铂80mg/m2静脉滴注,分割为1-3天使用,21天为1周期。2个周期后评价近期疗效。结果:32例患者均可评价疗效和毒副反应,其中CR 2例,PR 13例,SD 10例,PD 7例。有效率46.9%(15/32),疾病控制率78.1%(25/32)。主要毒性反应为骨髓抑制和胃肠反应。结论:赫赛汀联合NP(长春瑞滨+顺铂)方案是治疗蒽环类耐药晚期乳腺癌有效的解救方案,不良反应可耐受。
Objective:To evaluate the efficacy and toxicity of Herceptin combined with vinorelbine (NVB) and cisplatin(DDP) in treatment of metastatic breast cancer patients failed to anthracycline - based chemotherapy. Meth- ods : All 32 metastatic breast cancer patients failed to anthracycline - based chemotherapy were treated with Herceptin combined with NP. Herceptin was used by the way of intravenous drip at the first time with a dose of 8mg/kg the day before chemotherapy, then continuous to use by the dose of 6mg/kg. Vinorelbine with a dose of 25mg/m2 was given in- travenously at the first day and the 8th day, cisplatin 80mg/m2 was given intravenously from the first day to the third day. The regiment was repeated every 21 days and the clinical response was assessed after two cycles. Results:All 32 patients could be evaluated,2 patients achieved complete response (CR), 13 patients partial (PR), 10 patients stable disease (SD), and 7 patients progressive disease (PD). The response rate was 46.9% (15/32)and the disease con- trol rate was 78.1% (25/32). The major side effects were bone marrow suppression and gastrointestinal effects. Con- clusion : Combined chemotherapy of Herceptin plus NP is effective and safe in the treatment of failed to anthracycline -based chemotherapy metastatic breast cancer.
出处
《现代肿瘤医学》
CAS
2014年第7期1564-1566,共3页
Journal of Modern Oncology
基金
昆明医科大学研究生创新基金(编号:2013N06)
关键词
赫赛汀
长春瑞滨
顺铂
乳腺癌
Herceptin
vinorelbine
cisplatin
breast cancer